SEVELAMER CARBONATE - Generic Drug Details

What are the generic sources for sevelamer carbonate and what is the scope of patent protection?

Sevelamer carbonate is the generic ingredient in two branded drugs marketed by Genzyme, Aurobindo Pharma, Bionpharma, Chartwell Rx, Dr Reddys, Impax, Invagen Pharms, Lupin Ltd, Macleods Pharms Ltd, Strides Pharma Intl, Torrent, Sanofi, Amneal Pharms Co, Arthur Grp, Epic Pharma Llc, Impax Labs Inc, Micro Labs, Navinta Llc, Rising, Shandong Xinhua, Strides Pharma, and Zydus Pharms, and is included in twenty-eight NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sevelamer carbonate has thirty patent family members in eighteen countries.

There are seventeen drug master file entries for sevelamer carbonate. Thirty-three suppliers are listed for this compound.

Summary for SEVELAMER CARBONATE

International Patents:	30
US Patents:	1
Tradenames:	2
Applicants:	22
NDAs:	28
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	33
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	56
Patent Applications:	770
Drug Prices:	Drug price trends for SEVELAMER CARBONATE
What excipients (inactive ingredients) are in SEVELAMER CARBONATE?	SEVELAMER CARBONATE excipients list
DailyMed Link:	SEVELAMER CARBONATE at DailyMed

See drug prices for SEVELAMER CARBONATE

Recent Clinical Trials for SEVELAMER CARBONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jemincare	PHASE2
China National Center for Cardiovascular Diseases	PHASE4
Alebund Pharmaceuticals	PHASE3

See all SEVELAMER CARBONATE clinical trials

Pharmacology for SEVELAMER CARBONATE

Drug Class	Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for SEVELAMER CARBONATE

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for SEVELAMER CARBONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RENVELA	Powder for Oral Suspension	sevelamer carbonate	0.8 g/packet and 2.4 g/packet	022318	1	2009-12-30
RENVELA	Tablets	sevelamer carbonate	800 mg	022127	1	2008-12-04

US Patents and Regulatory Information for SEVELAMER CARBONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent	SEVELAMER CARBONATE	sevelamer carbonate	FOR SUSPENSION;ORAL	215909-001	Feb 27, 2025		DISCN	No	No
Macleods Pharms Ltd	SEVELAMER CARBONATE	sevelamer carbonate	FOR SUSPENSION;ORAL	207291-001	Apr 25, 2024	AB	RX	No	No
Navinta Llc	SEVELAMER CARBONATE	sevelamer carbonate	TABLET;ORAL	219931-001	Oct 27, 2025	AB	RX	No	No
Dr Reddys	SEVELAMER CARBONATE	sevelamer carbonate	FOR SUSPENSION;ORAL	210464-002	Oct 25, 2018	AB	RX	No	No
Strides Pharma	SEVELAMER CARBONATE	sevelamer carbonate	TABLET;ORAL	211915-001	May 9, 2024	AB	RX	No	No
Rising	SEVELAMER CARBONATE	sevelamer carbonate	TABLET;ORAL	204451-001	Nov 29, 2018	AB	RX	No	No

Expired US Patents for SEVELAMER CARBONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi	RENVELA	sevelamer carbonate	TABLET;ORAL	022127-001	Oct 19, 2007
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009
Sanofi	RENVELA	sevelamer carbonate	TABLET;ORAL	022127-001	Oct 19, 2007
Sanofi	RENVELA	sevelamer carbonate	TABLET;ORAL	022127-001	Oct 19, 2007

EU/EMA Drug Approvals for SEVELAMER CARBONATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi B.V.	Renvela	sevelamer carbonate	EMEA/H/C/000993Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues to control the development of renal bone disease.	Authorised	no	no	no	2009-06-09
Sanofi B.V.	Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)	sevelamer carbonate	EMEA/H/C/003971Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/L.Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.	Authorised	no	no	no	2015-01-15

International Patents for SEVELAMER CARBONATE

Country	Patent Number	Title	Estimated Expiration
Israel	189967	תכשירי אבקה המכילים סבלאמר קרבונט (Powder formulations containing sevelamer carbonate)
Spain	2556217
New Zealand	566542	Sachet formulation for amine polymers
China	101272762	Sachet formulation for amine polymers
Slovenia	1924246
Poland	1924246

Supplementary Protection Certificates for SEVELAMER CARBONATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0716606	C00716606/01	Switzerland		PRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004
0716606	C300080	Netherlands		PRODUCT NAME: SEVELAMER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SEVELAMER HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/99/123/001-00420000128 20000128
0716606	49/2009	Austria		PRODUCT NAME: SEVELAMERCARBONAT; REGISTRATION NO/DATE: EU/1/09/521/001- EU/1/09/521/007 20090610
0716606	6/2002	Austria		PRODUCT NAME: SEVELAMER SOWIE DESSEN PHARMAZEUTISCH VERTRAEGLICHEN SALZE; REGISTRATION NO/DATE: EU/1/99/123/001 - EU/1/99/123/004 20000128
0716606	C300428	Netherlands		PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610
0716606	02C0011	France		PRODUCT NAME: SEVELAMER; REGISTRATION NO/DATE: EU/1/99/123/001 20000128

SEVELAMER CARBONATE: PATENT LANDSCAPE AND MARKET DYNAMICS

Last updated: February 19, 2026

This analysis examines the patent status and market trajectory of sevelamer carbonate, a phosphate binder used in chronic kidney disease (CKD) patients. Key patents protecting the compound and its formulations are nearing expiration, enabling generic competition. The market is characterized by a shift towards lower-cost generics, influencing pricing and market share.

What is the Patent Status of Sevelamer Carbonate?

The primary patents covering sevelamer carbonate, specifically those related to its composition of matter and methods of use, have either expired or are in their final stages of protection.

• Composition of Matter Patents: Original patents for sevelamer, including its carbonate salt, have largely expired. For instance, U.S. Patent 5,496,805, which claimed sevelamer and its pharmaceutically acceptable salts, expired in 2013.
• Formulation Patents: Patents related to specific formulations, such as delayed-release or extended-release versions, have provided extended market exclusivity. However, many of these are also nearing or have already reached expiration. For example, patents covering certain tablet or capsule formulations have expiration dates throughout the mid-to-late 2020s. The availability of multiple generic versions suggests significant patent erosion.
• Exclusivity Periods: The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) has allowed for extensions of patent terms. However, the window for new formulation patents to significantly delay generic entry for established drugs like sevelamer carbonate is narrowing.

Who Are the Key Market Players?

The sevelamer carbonate market comprises originators and a growing number of generic manufacturers.

• Originator: Genzyme Corporation (a Sanofi company) was the primary developer and marketer of Renvela®, the originator brand.
• Generic Manufacturers: A significant number of pharmaceutical companies have entered or are preparing to enter the sevelamer carbonate market with generic versions. These include:
  • Teva Pharmaceuticals Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • Viatris Inc. (formed from the merger of Mylan and Pfizer's Upjohn)
  • Zydus Lifesciences Ltd. (formerly Cadila Healthcare)

The presence of these multiple players indicates a competitive landscape driven by patent expirations.

What is the Market Size and Growth Trajectory?

The global market for sevelamer carbonate has been substantial, driven by the prevalence of CKD and hyperphosphatemia. However, the market is undergoing a transition.

• Historical Market Value: The sevelamer carbonate market, primarily led by Renvela®, reached significant sales figures, estimated to be in the hundreds of millions of U.S. dollars annually at its peak. For instance, Genzyme reported billions in revenue for sevelamer products globally.
• Impact of Generics: The introduction of generic sevelamer carbonate has led to a substantial decline in the average selling price (ASP). This price erosion is typical in pharmaceutical markets following patent expiry and the entry of multiple generic competitors.
• Market Volume: While ASP has decreased, the overall market volume in terms of units dispensed has likely increased due to greater affordability.
• Projected Growth: Future market growth for sevelamer carbonate is expected to be modest, largely driven by volume increases rather than price appreciation. The market will be increasingly fragmented, with generic manufacturers competing on price and market access. The overall therapeutic class for phosphate binders is expected to grow due to an aging population and increasing incidence of CKD, but sevelamer carbonate's share within that class will face intense generic pressure.

How Do Pricing and Reimbursement Policies Affect the Market?

Pricing and reimbursement policies are critical determinants of market access and sales volume for sevelamer carbonate.

• Price Erosion: The most significant impact on pricing is the widespread availability of generic sevelamer carbonate. Payers, including government programs (e.g., Medicare, Medicaid in the U.S.) and private insurers, actively promote the use of generics due to their lower cost.
• Rebate Structures: Pharmaceutical companies, both originators and generics, engage in rebate negotiations with pharmacy benefit managers (PBMs) and directly with payers. These rebates influence which products are favored on formularies.
• Formulary Placement: Preferred formulary status is crucial for market share. Generics, offering significant cost savings, often secure preferred placement. This can lead to a rapid displacement of the originator brand.
• Medicare Part D: In the U.S. Medicare Part D program, the shift to generics for drugs like sevelamer carbonate has a direct impact on drug spending for beneficiaries and program costs.
• International Markets: Pricing and reimbursement policies vary significantly by country. In many European markets, the national health systems often negotiate prices aggressively, accelerating generic adoption.

What are the Key Regulatory Considerations?

Regulatory approvals and post-market surveillance are essential for sevelamer carbonate products.

• FDA and EMA Approvals: Sevelamer carbonate products require approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Generic manufacturers must demonstrate bioequivalence to the reference listed drug (RLD).
• Bioequivalence: The primary regulatory hurdle for generics is demonstrating bioequivalence. This involves showing that the generic drug is absorbed into the bloodstream at the same rate and to the same extent as the RLD.
• Labeling: Generic labels must be the same as the RLD's label, except for minor differences in inactive ingredients.
• Post-Market Surveillance: Like all pharmaceuticals, sevelamer carbonate products are subject to ongoing post-market surveillance to monitor for adverse events and ensure product quality.
• ANDA Filings: The Abbreviated New Drug Application (ANDA) process allows for the approval of generic drugs, facilitating market entry once patents and exclusivities expire. The FDA has approved multiple ANDAs for sevelamer carbonate.

What are the Clinical Use Cases and Therapeutic Alternatives?

Sevelamer carbonate is prescribed to manage hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis.

• Primary Indication: Hyperphosphatemia is a common complication in CKD, particularly in patients undergoing hemodialysis. Elevated phosphate levels can lead to secondary hyperparathyroidism, renal osteodystrophy, and cardiovascular calcification.
• Mechanism of Action: Sevelamer carbonate is a non-calcium, non-aluminum based phosphate binder. It works in the gastrointestinal tract by binding to dietary phosphate and preventing its absorption into the bloodstream. The carbonate form also releases bicarbonate, which can help correct metabolic acidosis.
• Therapeutic Alternatives: Several other classes of phosphate binders are available, offering different mechanisms of action and risk profiles. These include:
  • Calcium-based Binders: Calcium carbonate and calcium acetate. These are generally less expensive but carry risks of hypercalcemia and vascular calcification accumulation.
  • Other Non-Calcium, Non-Aluminum Binders:
    • Lanthanum Carbonate: (e.g., Fosrenol®). Works similarly to sevelamer.
    • Ferric Phosphate Binders: (e.g., Auryxia®). Binds phosphate and provides iron, which can be beneficial for anemic CKD patients.
    • Supratek™ (Magnesium Carbonate/Hydroxide/Oxide): Another option with a different binder profile.
  • Dietary Restrictions: Limiting dietary phosphate intake is a fundamental strategy.

The availability of multiple alternatives creates a competitive environment within the broader hyperphosphatemia management space. Patient-specific factors, cost, payer policies, and physician preference influence treatment selection.

What is the Future Outlook for Sevelamer Carbonate?

The future outlook for sevelamer carbonate is characterized by increased generic penetration and price competition.

• Dominance of Generics: Generic versions will continue to capture the vast majority of the market share. Brand loyalty for originator products in the face of significantly cheaper generics is limited.
• Price Pressure: Ongoing price pressure is expected as more generic manufacturers compete. This could lead to further consolidation among smaller generic players.
• Market Segmentation: While the overall market may not grow substantially in value, demand is likely to remain stable due to the chronic nature of CKD. The market will be segmented by price points offered by various generic manufacturers.
• Innovation in Therapeutic Class: The broader phosphate binder market may see innovation, with new agents or formulations emerging. However, sevelamer carbonate itself is a mature product, and significant new patent-protected innovation on the molecule is unlikely.
• Geographic Expansion: Generic entry in emerging markets, where cost is a primary driver for healthcare access, could represent a growth avenue for sevelamer carbonate.

Key Takeaways

• Patent Expirations: Sevelamer carbonate's core composition of matter patents have expired, with formulation patents also nearing or at expiration, facilitating broad generic entry.
• Competitive Landscape: The market is now dominated by multiple generic manufacturers, leading to intense price competition.
• Market Dynamics: The market value has declined due to generic price erosion, although unit volume is likely stable or increasing.
• Pricing Impact: Generic availability has significantly reduced the average selling price, driven by payer and PBM negotiations and formulary decisions.
• Therapeutic Alternatives: Sevelamer carbonate competes with calcium-based binders, lanthanum carbonate, and ferric phosphate binders, with treatment choice influenced by cost, efficacy, and patient factors.
• Future Outlook: The future is characterized by sustained generic dominance, ongoing price pressure, and stable demand driven by the prevalence of CKD.

Frequently Asked Questions

1. Will the originator brand (Renvela®) maintain any market share? The originator brand will likely retain a small market share for patients with specific payer contracts or those who, for unaddressed reasons, continue to request the brand. However, this share is expected to be minimal as generics offer substantial cost savings.

2. Are there any new patent applications or strategies being employed to extend sevelamer carbonate exclusivity? While companies can file patents on new formulations, manufacturing processes, or methods of use, the ability of such patents to create significant market exclusivity for a mature molecule like sevelamer carbonate is limited. Most robust patent protection has already expired.

3. How does the availability of sevelamer carbonate impact the overall cost of CKD management? The availability of cost-effective generic sevelamer carbonate contributes to reducing the overall drug expenditure within CKD management. This allows healthcare systems to allocate resources to other areas of patient care or invest in newer therapies.

4. What are the primary reasons for physicians to switch patients from sevelamer carbonate to alternative phosphate binders? Physicians may switch patients for several reasons: the emergence of more cost-effective alternatives (including generics of other binders), patient tolerance issues with sevelamer carbonate, the presence of co-morbidities that benefit from specific binders (e.g., iron deficiency with ferric phosphate binders), or payer mandates favoring other agents.

5. What is the typical timeline from initial generic approval to significant market share capture for a drug like sevelamer carbonate? For a widely prescribed drug with a large patient base and significant price differential, the shift to generic dominance can occur rapidly, often within 12-24 months of the first generic approval, assuming multiple generics launch concurrently or in close succession.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm [2] Genzyme Corporation. (2010). Annual Report 2010. [3] Teva Pharmaceuticals Industries Ltd. (Various Years). Annual Reports. [4] Lupin Limited. (Various Years). Annual Reports. [5] Dr. Reddy's Laboratories Ltd. (Various Years). Annual Reports. [6] Apotex Inc. (Internal Company Data - Publicly Available Information through Regulatory Filings and Press Releases). [7] Viatris Inc. (Various Years). Annual Reports. [8] Zydus Lifesciences Ltd. (Various Years). Annual Reports. [9] National Kidney Foundation. (n.d.). Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines. Retrieved from https://kdigo.org/